Peroxisomal beta-oxidation of palmitoyl-CoA in human liver homogenates and its deficiency in the cerebro-hepato-renal (Zellweger) syndrome.
The presence of a beta-oxidation system in peroxisomes has been well documented. Rather than a duplicate of the mitochondrial beta-oxidation system, peroxisomes seem specially equipped to initiate the oxidation of very-long-chain fatty acids. Thus, the accumulation of very-long-chain fatty acids in tissues and body fluids from patients with a limited (X-linked adrenoleukodystrophy) or generalized (cerebro-hepato-renal (Zellweger) syndrome, infantile Refsum disease, neonatal adrenoleukodystrophy) peroxisomal dysfunction probably results from an impairment in the peroxisomal beta-oxidation system. In order to study this, we have developed an original assay which allows measurement of the overall peroxisomal beta-oxidation activity in human liver homogenates. Compared to controls, a strong deficiency of this activity was detected in liver from Zellweger patients using palmitoyl-CoA as a substrate.
D000214:Acyl Coenzyme A / Q000378:metabolism*; D000818:Animals; D002499:Centrifugation, Density Gradient; D006801:Humans; D008052:Lipid Metabolism, Inborn Errors / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008830:Microbodies / Q000378:metabolism*; D010084:Oxidation-Reduction; D010171:Palmitoyl Coenzyme A / Q000378:metabolism*; D051381:Rats; D013347:Subcellular Fractions / Q000378:metabolism; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
D000214:Acyl Coenzyme A; D010171:Palmitoyl Coenzyme A; D001619:beta-N-Acetylhexosaminidases